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Background: Tuberculosis (TB) is the leading cause of death related to HIV worldwide. This study analyzes the
survival of People Living with HIV (PLHIV) reporting cough without bacteriological confirmation of TB and identify
factors associated with death.
Methods: Prospective cohort with a consecutive sample of PLHIV, aged ≥ 18 years. Patient inclusion criteria were
complaint of current cough of any duration at the time of the first study interview or during their subsequent
routine visits to health services and for whom AFB sputum smear was either negative or not performed during the
whole follow-up period. Kaplan-Meier method was used to calculate the probability of survival. We estimated the
Hazard Ratio (HR) in bivariate and multivariate Cox regression analyses.
Results: Mortality was 4.6 per 100 py; 73% were receiving HAART at recruitment. Average time from the first
recorded date of cough until empirical treatment for tuberculosis was six months. Mortality was higher when the
CD4 count was low (HR = 5.3; CI 95%: 3.2-9.0; p = 0.000), in those with anemia (HR = 3.0; CI 95%: 1.6-5.6; p = 0.001)
and with abnormal chest X-rays (HR = 2.4; CI 95%: 1.4-4.0; p = 0.001). Mortality was higher in those receiving
empirical TB treatment (HR = 2.4; CI 95%: 1.4-4.0; p = 0.002), but only in those with normal X-rays, no history of
tuberculosis and no bacteriology requests. Empirical treatment for TB was more frequent in PLHIV with low CD4
counts, anemia, history of opportunistic infections, weight loss, previous tuberculosis, negative bacteriology test
(as opposed to not having a test) and abnormal chest X-ray.
Conclusions: Higher mortality in PLHIV reporting a current cough without bacteriological confirmation of
tuberculosis was identified for those with a CD4 cell count <200, abnormal chest X-ray, anemia and empirical
treatment for tuberculosis. Mortality was not significantly higher in those empirically treated for TB, who had three
characteristics suggestive of the disease (abnormal chest X-ray, history of TB treatment, AFB sputum smear or M.tb
culture testing). Routine cohorts are not an adequate setting to evaluate the impact of empirical treatment for TB
on the mortality of PLHIV.
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The widespread use of HAART has caused a decline in
mortality rates in PLHIV [1], although rates are still higher
in developing countries than in developed countries [2].
Population surveys and autopsy studies have shown that
many of these deaths are due to undiagnosed and there-
fore untreated tuberculosis (TB) [3-5]. TB is the leading
cause of death related to HIV worldwide [3,6-9] contribut-
ing to an estimated 24% of deaths [1], and this alone may
prevent meeting the WHO target of halving the 1990
levels of TB mortality [6]. Simultaneous antiretroviral and
TB treatment has reduced mortality of dual TB/HIV cases
in observational studies [10-12] and controlled trials
[13] and is recommended by WHO [6]. However, in the
severely immune-suppressed it is difficult to diagnose
tuberculosis or even to establish criteria for suspecting
active disease.
In developing countries, the diagnosis of pulmonary
TB is heavily dependent on AFB sputum smear micros-
copy, which has low sensitivity among PLHIV [14], who
often present extra pulmonary or sputum smear-negative
pulmonary TB, resulting in late diagnosis [15] and there-
fore either delayed or no treatment [16]. This has led to
the suggestion that empirical treatment of tuberculosis
(i.e. without microbiological confirmation) may be desir-
able in some circumstances, given the existing limitations
for the diagnosis of negative AFB sputum smear pulmon-
ary TB in PLHIV, and the high rates of TB mortality in
this population [3]. In spite of this, there has been little re-
search into the outcomes of HIV-positive TB suspects
[17]. Moreover, in the routine of health services, attending
physicians may not always follow standardized protocols
and it remains unclear as to how these patients are se-
lected for empirical TB treatment.
Recife, the capital of Pernambuco, Northeast Brazil, has
the 4th highest rate of TB (92/100.000 inhabitants in 2011)
in the country, and high mortality rates from TB (6.1/
100.00 inhabitants in 2011) [18]. In a routine care setting
in Recife, we estimated the probability of survival and the
mortality rate of PLHIV complaining of a cough, since this
is the main symptom for suspected TB, as recommended
by the Brazilian Ministry of Health) [18]. The presence of a
cough of any duration is one of the four symptoms recom-
mended for TB screening amongst PLHIV [19]. We also
investigated factors associated with death, with emphasis
on empirical treatment for tuberculosis.
Methods
From an original cohort of PLHIV attending two HIV
referral health centers in Recife, recruited from 2007 to
2010 and followed up to June 2011, we selected a con-
secutive sample of individuals who reported a cough in
order to estimate the probability of survival and mortal-
ity rates. We also identified the factors associated withdeath with emphasis on empirical TB treatment. The pa-
tient inclusion criteria were: aged ≥ 18 years, and com-
plaining of a current cough of any duration at the time
of the first study interview, or during their subsequent
routine visits to health services, and for whom AFB
sputum smear examination or Mycobacterium tubercu-
losis (M.tb) culture tests were either negative or not per-
formed (either because the attending physician did not
request the test or because the patient did not have spu-
tum or simply did not perform the requested tests) dur-
ing the whole follow-up period.
We excluded those with positive bacteriology results
(sputum smear microscopy or culture for M.tb) because
they were confirmed TB cases. Cough was used in the
study to indicate that patients were respiratory symp-
tomatic and thus, presenting a higher probability of pul-
monary TB.
The outcome of interest was time until death by any
cause, with the exception of external causes (accidents,
homicides and suicides). Deaths were identified through
record linkage of cohort subjects to deaths during the
follow-up period in the Mortality Information System of
Pernambuco (SIM-PE), using the probabilistic linkage
program RecLink III [20].
The main exposure of interest was empirical treatment
for TB in the context of the study hypothesis as a pro-
tective factor for mortality in PLHIV. Treatment for
pulmonary TB was initiated by the attending physician
based on their clinical judgment. Antiretroviral therapy
and TB treatment are distributed free of charge by the
health services, and are restricted to cases notified to the
System of Notification of Infectious Diseases (SINAN)/
Pernambuco (PE).
Other explanatory variables were sex, age, socioeconomic
status (individual monthly income, literacy and employ-
ment), and lifestyle (use of illicit drugs, alcohol and to-
bacco). Alcohol consumption, based on reported number
of drinks per day, was classified according to the CDC
[21], into abstainers, light drinkers and heavy drinkers
(>two drinks/day for men and > one drink/day for women).
Smoking was classified into: never smoker, former smoker
(did not smoke at the time of the study nor during the pre-
ceding 6 months), and current smoker (smoked at the time
of the study or quit less than six months before) [22].
Data was also collected on general health (Body Mass
Index-BMI, anemia, loss of weight reported at baseline)
and variables related with HIV and TB. HIV-related vari-
ables included CD4 T-cell count and opportunistic dis-
eases during the previous three months. A combination
of three different antiretroviral drugs was categorized as
either using HAART or not, on entry to the cohort.
The CD4 T-cell count was measured during the follow-
up period and was the only time-varying variable in the
survival analysis, categorized as ≥ 200 cells/mm3 and < 200
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history of previous TB treatment and bacteriology testing
(whether negative or not performed).
Individuals were interviewed by a health professional
using a tailored questionnaire, after signing the Statement
of Informed Consent. Information regarding complaining
of a cough, results of laboratory tests, and treatment for
TB and HIV was abstracted from medical records using a
specific form. Patients who reported a cough of any dur-
ation during the routine clinical visits were enrolled in
this cohort.
Statistical analysis
The follow-up period was considered from the time a
cough was first registered until failure (death) or censoring:
at the end of the study or on death from external causes
(accidents, homicides or suicides). The Kaplan-Meier (KM)
method was used to calculate the probability of survival for
the whole study population and stratified for empirical
treatment for TB (yes/no) and for CD4 cell count (≥ 200
cells/mm3 and < 200 cells/mm3. To identify factors
associated with death we estimated the Hazard Ratio
(HR) in bivariate and multivariate Cox regression ana-
lyses with 95% Confidence Intervals (CI) and p values to
evaluate the statistical significance. We assessed the
proportional-hazards assumption for each variable stud-
ied. Variables significantly associated with death in the
bivariate analysis at a p value ≤ 0.20 were introduced
into the multivariate model, according to their statistical
significance and clinical and epidemiological import-
ance. The final model retained variables associated with
death at p value ≤ 0.05.
A second unplanned analysis was conducted to inves-
tigate an unexpected result: the higher mortality in
those who received empirical treatment for TB. First, weFigure 1 Flow chart of the study population.investigated the characteristics of those who received em-
pirical treatment (bivariate and multivariate logistic regres-
sion analyses) to verify whether these characteristics could
explain the higher mortality. Secondly, we estimated the
effect of the empirical treatment separately in those we
considered less likely to have had TB and those more likely
to have had TB, based on the presence of three indicators
for the likelihood of TB: bacteriology testing, an abnormal
chest X-ray and a history of previous TB treatment.
Our hypothesis was that empirical treatment for TB
would only be associated with higher mortality rates in
those unlikely to have had TB, proposing that treatment
may have been introduced as a desperate measure given
the severity of the HIV disease, (where mortality is very
high). Data analysis was undertaken using STATA 11.2.
Ethical approval
This study is part of the project “Clinical-epidemio-
logical study of co-infection tuberculosis/HIV in Recife”
which was approved by the Research Ethics Committee
at the Universidade Federal de Pernambuco (CEP/CCS/
UFPE 254/05).
Results
From 2382 PLHIV attending the referral centers during
the study period, 893 complained of a cough of any
duration at any time during follow-up. Of these, 93 were
excluded: 62 presented sputum smear positive, 21 had
started TB treatment before registering a cough, eight
presented a positive M.tb culture during the follow-up,
and two died on the day a cough was recorded. The final
analysis included 800 patients, with 698 censored, 691
surviving to the end of the study and 7 deaths from exter-
nal causes and 95 deaths from clinical causes (failures)
(Figure 1).
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graphic, socioeconomic and lifestyle factors. Most patients
(59%) were male and 55% were aged under 40 years. Over
80% were literate and 47.5% had a monthly income ≥ 1
minimum wage (on average 170 dollars over the study
period) and 25% were employed. Most were either current
(40%) or former (23%) smokers. Past/current use of illicit
drugs was reported by one in three patients.
Table 2 shows the distribution of general health vari-
ables, variables related to HIV and variables related to
TB. At baseline, 62% had a BMI between 18.5 kg/m2 and
24.9 kg/m2 (eutrophic), 11% were underweight and 27%
were overweight/obese; 45% had anemia and half reportedTable 1 Frequency distribution and bivariate Cox regression




Female 327 (40.9) 1
Males 473 (59.1) 1
Age
Age groups
< 40 years 437 (54.6) 1
≥ 40 years 363 (45.4) 0
Socioeconomic variables
Literate
Yes 678 (85.4) 1
No 116 (14.6) 1
Individual monthly income (MW)
≥ 1 374 (47.5) 1
< 1 413 (52.5) 1
Employment
Yes 191 (24.2) 1
No 599 (75.8) 2
Lifestyle variables
Alcohol consumption
Abstainer 497 (63.3) 1
Light drinker 189 (24.1) 0
Heavy drinker 99 (12.6) 0
Smoking status
Never smoker 296 (37.1) 1
Former smoker 180 (22.6) 0
Current smoker 322 (40.4) 1
Illicit drug use
Never 553 (69.5) 1
Past or current 243 (30.5) 1opportunistic diseases in the three months before recruit-
ment. During follow-up, almost all (99.4%) underwent at
least one CD4 cell count measurement and 73.2% used
HAART at entry. Previous TB treatment was reported by
22.7% and one hundred and seventy one (21%) individuals
received empirical treatment for tuberculosis during
follow-up. Bacteriology tests (AFB sputum smear or M.tb
culture) were not performed in 61% (492) of the whole co-
hort, and this percentage dropped to 40.9% among the
171 patients who initiated presumptive TB treatment, dur-
ing follow-up (data not shown). Half of the 492 people
who did not undergo bacteriological testing was reported
to have no sputum. Patients who did not undergo AFBanalysis of the association between demographic,
plaining of cough, Recife, 2010
R (CI 95%) P value Proportionality test
p value
.0
.62 (1.0 – 2.5) 0.031 0.3761
.0
.91 (0.6 – 1.4) 0.643 0.1676
.0
.4 (0.8 – 2.3) 0.198 0.7981
.0
.1 (0.9 – 1.4) 0.272 0.2641
.0
.4 (1.3 – 4.6) 0.006 0.6009
.0 0.003
.4 (0.2 - 0.7)
.6 (0.3 - 1.2) 0.193 0.3628
.0
.6 (0.3 - 1.2) 0.159 0.3839
.4 (0.9 - 2.1) 0.170
.0
.0 (0.6 - 1.5) 0.904 0.2202
Table 2 Frequency distribution and bivariate Cox regression analysis of the association between general health,
variables related to HIV and TB with death of PLHIV complaining of cough, Recife, 2010




18.5 to 24.9 kg/m2 483 (62.4) 1.0
< 18.5 kg/m2 85 (11.0) 2.0 (1.1 – 3.4) 0.015 0.2341
≥ 25 kg/m2 206 (26.6) 0.6 (0.3 – 1.0) 0.056
Anemia
No 402 (54.6) 1.0
Yes 334 (45.4) 5.6 (3.1 – 10.0) 0.000 0.9383
Loss of weight reported at baseline
No 422 (56.1) 1.0
Yes 330 (43.9) 2.2 (1.4 - 3.4) 0.000 0.3383
Variables related to HIV
HAART (baseline)
No 214 (26.8) 1.0
Yes 585 (73.2) 1.3 (0.8 - 2.1) 0.299 0.0055
CD4 cell count (time varying)
≥ 200 - 1.0
< 200 - 9.1 (5.9 – 14.0) 0.000 0.5200
Opportunistic disease reported at baseline
No 405 (50.6) 1.0
Yes 395 (49.4) 2.0 (1.3 – 3.0) 0.001 0.1302
Variables related to tuberculosis
AFB sputum smear or M. Tb culture during follow-up
Not performed 492 (61.5) 1.0
Negative 308 (38.5) 1.7 (1.1 – 2.5) 0.010 0.9815
Chest X-ray
Normal 364 (45.5) 1.0
Abnormal 154 (19.3) 4.0 (2.4 - 6.6) 0.000
Not performed 282 (35.3) 1.7 (1.0 - 2.9) 0.045 0.0301
Empirical TB treatment during follow-up
No 629 (78.6) 1.0
Yes 171 (21.4) 7.3 (4.8 – 11.0) 0.000 0.8524
History of previous TB treatment
No 618 (77.3) 1.0
Yes 182 (22.7) 1.9 (1.2 - 2.9) 0.003 0.6722
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were similar to those who tested and were negative, in re-
lation to sex, age, CD4 cell count and HAART at baseline
(data not shown).
The mortality rate was 4.6 per 100 py. Figure 2 shows
the Kaplan-Meier 85.4% probability of survival by the end
of the follow-up period (3.9 years), the KM for empiricalTB treatment (Yes= 56.2% and No= 93.1%) and the KM
for CD4 < 200 cells/mm3 (52.2%) and CD4 ≥ 200 cells/
mm3 (93.6%).
The median time of follow-up was 2.8 years. The mor-
tality rate among those with no bacteriology testing was
3.4 per 100 py and among those who presented negative
bacteriology tests 6.4 per 100 py. Mortality was higher in
Figure 2 Kaplan Meier estimate for survival probability of PLHIV with Presumptive TB. A) KM estimate for survival probability of the whole
study population with 95% CI and logrank test. B) KM estimate for survival probability stratified by empirical treatment for tuberculosis with 95%
CI and logrank test. C) KM estimate for survival probability stratified by CD4 cell count with 95% CI and logrank test.
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py), than for those who did not (2.1 per 100 py). The
average time from registering a cough until TB treatment
was almost six months, and was greater for those who
died (183 days) than for those who did not (153 days).
However, this was not statistically significant (p = 0.499).
We verified that those who did not report a history of
previous TB treatment and those who had normal chest
X-rays presented a greater average time from the registra-
tion of a cough until TB treatment compared with those
who reported a history of previous TB treatment and
those with abnormal chest X-rays, respectively, and the
differences were statistically significant. There was no dif-
ference in the average time from registering a cough until
TB treatment between patients who did not undergo AFB
sputum smear or M.tb culture testing during follow-up
and those who tested negative.
Tables 1 and 2 demonstrate the crude association be-
tween death and the demographic, socioeconomic and
lifestyle variables; variables related to general health, aswell as those related to HIV and TB, which were statisti-
cally significant at a p value ≤ 0.20.
Table 3 illustrates the final adjusted model. Risk of death
was higher in those with anemia (HR = 2.8), during periods
of low CD4 count (HR = 5.1), for those with an abnormal
chest X-ray (HR = 1.9) and those receiving empirical treat-
ment for TB (HR = 3.7). Light drinkers presented a lower
risk of death compared to abstainers. The proportional-
hazards assumption in the final model was respected
(phtest = 0.7073).
Table 4 compares those who did and did not receive
empirical treatment for TB. Treated subjects were more
likely to have characteristics suggestive of severe HIV
disease (low CD4, opportunistic infections) and charac-
teristics suggestive of tuberculosis (abnormal chest X-
ray, history of TB treatment, bacteriology testing) and
characteristics suggestive of both TB and severe HIV: re-
ported weight-loss and anemia.
It is not demonstrated in the table that 74% of patients
with the three characteristics suggestive of TB received
Table 3 Multivariate Cox regression analysis of the
association between the variables studied and death of
PLHIV complaining of cough, Recife, 2010
N (%) HR (CI 95%) P value
Alcohol consumption
Abstainer 497 (63.3) 1.0
Light drinker 189 (24.1) 0.4 (0.2 - 0.9) 0.049
Heavy drinker 99 (12.6) 1.0 (0.5 - 1.9) 0.907
Anemia
No 402 (54.6) 1.0
Yes 334 (45.4) 2.8 (1.5 - 5.3) 0.001
CD4 cell count (time varying)
≥ 200 — 1.0
< 200 5.1 (3.1 – 8.6) 0.000
Chest X-ray
Normal 364 (45.5) 1.0
Abnormal 154 (19.3) 1.9 (1.1 – 3.3) 0.001
Not performed 282 (35.3) 1.5 (0.8 – 2.7) 0.146
Empirical TB treatment
during follow-up
No 629 (78.6) 1.0
Yes 171 (21.4) 3.7 (2.2 – 6.3) 0.000
Phtest (p = 0.7073).
Table 4 Multivariate Logistic regression analysis of the
association between the variables studied and empirical





CD4 cell count (time varying)
≥ 200 cel/mm3 1.0
< 200 cel/mm3 3.0 (1.8 – 4.8) 0.000
Anemia
No 1.0
Yes 3.4 (2.1 – 5.5) 0.000
Loss of weight reported at baseline
No 1.0
Yes 1.9 (1.2 – 3.0) 0.008
Opportunistic disease reported at baseline
No 1.0
Yes 2.0 (1.2 – 3.4) 0.005
History of previous TB treatment
No 1.0
Yes 2.3 (1.4 – 3.8) 0.002
Chest X-ray
Normal 1.0
Abnormal 2.0 (1.1 – 3.5) 0.016
No performed 0.72 (0.4 – 1.3) 0.253
Sputum smear ABF or M. tuberculosis
culture during follow-up
No 1.0
Negative 2.4 (1.5 - 3.8) 0.000
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significantly higher in those treated (HR = 1.5; p = 0.590).
Less than 10% of those with none of the 3 characteristics
suggestive of TB received empirical treatment, which in
this group was significantly associated with a marked in-
crease in mortality (HR = 14.3; p <0.001).Discussion
The mortality rate encountered in our study, 4.6 per 100
person-years, was lower than in similar populations in
Zimbabwe (17.9/100py) [17] and South Africa (28.9 per
100 py) [23]. This could be due to a more frequent use
of HAART (73.2% in our study compared to 21.3% in
SA). HAART reduces case fatality in smear-negative pul-
monary TB [15].
Those who underwent bacteriology testing presented a
higher mortality rate (1.7 higher) when compared with
those who did not, although this was not significant in
the multivariate model. The request for bacteriology
tests may reflect the strength of the attending physician’s
suspicion of tuberculosis, and indicate a higher likeli-
hood of tuberculosis.
The highest increase in mortality occurred when pa-
tients presented a low CD4 cell count (< 200). This is con-
sistent with the literature: advanced immunosuppressionwas the main risk factor for death in PLHIV with negative
bacteriology tests and presumptive TB [17].
Chest X-ray investigation is recommended soon after a
cough to shorten delays in diagnosis and treatment of
smear negative pulmonary TB in PLHIV [1,24]. In our
study, 64.8% of the patients performed a chest X-ray, of
which one in three was abnormal. Abnormalities were
associated with empirical treatment for TB and were a
predictor of death, again in our view, indicating a higher
likelihood of tuberculosis.
We studied smoking, alcohol consumption, and illicit
drug use because these factors have been associated
with either TB/HIV disease progression or death in
PLHIV [25-28]. All three were very frequent in our
study population but none were associated with death
in the multivariate model. Abstemious subjects pre-
sented higher mortality, which in our view, is possibly a
consequence of ill health.
Contrary to our expectations, mortality was higher in
those who received empirical treatment for TB. If all
other factors were the same, we would expect that in
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they are respiratory symptomatic and thus, with a higher
probability of pulmonary TB), empirical TB treatment
would have improved prognosis [3,15-17], particularly
in this population with a high HAART uptake since the
start of follow-up [3,6].
To explore this further, we investigated characteristics
of those receiving empirical treatment: they had both
more characteristics suggesting TB and severe HIV dis-
ease. Mortality was not significantly higher in those
treated with three characteristics suggestive of TB (ab-
normal chest X-ray, history of previous TB treatment,
AFB sputum smear or M.tb culture testing).
In those without the three characteristics strongly sug-
gestive of TB, mortality was 14 times higher in those re-
ceiving empirical treatment. This is consistent with the
attending physician being more likely to introduce tu-
berculosis treatment as a final resource in patients more
likely to die. This could either be because there was an-
other cause for the cough or because of severe HIV dis-
ease, or both. Empirical treatment was more frequent
with a lower CD4 count, anemia, weight loss and those
who reported past opportunistic disease. A greater per-
centage (44.6%) of patients with a CD4 < 200 was treated
empirically for TB compared with only 15.5% of patients
with a CD4 cell count ≥ 200 (data not shown). Although
we performed a control for other predictors of mortality,
such as anemia, weight loss, and a low CD4 count, the
occurrence of residual confounding is very likely as the
measurements were not conducted very frequently: for
example, on average, a CD4 count was measured every
6 months. In a similar cohort it would be important to
ascertain that other potential diagnoses that may mimic
TB had not been overlooked [3]. Immune reconstitution
syndrome could have caused death due to unmasked TB
after the initiation of HAART. However, the impact of
this on the mortality rate in this cohort was probably di-
minished by the small number of patients who had used
HAART for less than one year.
Empirical treatment for TB may have been introduced
too late to prevent death, especially among those patients
who presented normal chest X-rays and did not report a
history of previous TB treatment. These findings reinforce
the need to speed up TB diagnosis and treatment among
those with presumptive TB and AFB sputum smear nega-
tive [19].
At the time of data collection there was no inter-
nationally accepted symptoms score system based on
evidence for diagnosing negative sputum pulmonary TB
in PLHIV [29], and treatment, based on clinical judgment,
was introduced on average, 6 months after a cough was
registered. To identify an optimum standardized rule for
TB screening among PLHIV, a meta-analysis of observa-
tional studies found that the presence of at least one ofthe symptoms: cough of any duration, fever, night sweats
and weight loss, had a sensitivity of 78.9% to identify TB
in PLHIV. Abnormal chest X-ray findings increased sen-
sitivity by 11% [29]. This evidence underlies the WHO
recommendation to introduce screening for TB in the
routine care of PLHIV [19].
One limitation of our study concerns that of observa-
tional studies to evaluate the effectiveness of empirical
treatment for TB, which was initiated by physicians dur-
ing routine care within the health services. Besides this,
the empirical treatment for TB did not follow a well-
defined protocol for screening TB, which would have en-
sured the early introduction of TB treatment, and also
avoid the misdiagnosis of other opportunistic diseases
that could present with cough. Furthermore, data on op-
portunistic diseases were collected only at baseline and
not during the follow-up period.
Observation studies on empirical TB treatment should
be used to evaluate the processes involved, e.g., prescrib-
ing practices, completeness of treatment, but not to evalu-
ate the impact of empirical treatment for TB, since there
is very strong residual confounding and the impact cannot
be evaluated accurately. Even so, we believe that it is very
important to reveal our results because, probably, this is a
very common situation in many settings, especially in the
developing world where the presumptive diagnosis of TB
in PLHIV occurs extensively.Conclusions
In this routine setting, the large majority of PLHIV with
strong indications of presenting with tuberculosis were
receiving empirical treatment, although late. Their mor-
tality was still a little higher than those with strong indi-
cations of TB who did not receive treatment, but this
could result from the stronger likelihood for them to
present with tuberculosis. Mortality was not significantly
higher in those patients empirically treated for TB, who
presented three characteristics suggestive of the disease
(abnormal chest X-ray, history of TB treatment, AFB spu-
tum smear or M.tb culture testing). Those with strong in-
dications of advanced HIV diseases were more likely to
receive empirical TB treatment (even when presenting
fewer indications of tuberculosis); those receiving treat-
ment in this group had a marked increase in mortality,
which most likely resulted from their advanced HIV dis-
ease, and possibly from other causes for the cough. Al-
though we performed a control for the CD4 cell count in
the analysis, we believe that severe HIV disease was a very
strong confounder of the association between empirical
TB treatment and mortality.Competing interests
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